Emergent BioSolutions Inc. Common Stock (EBS)

NARCAN's market lead persists despite pricing pressure, signaling the brand's resilience as the company executes its turnaround.

Revenue fell 52% on delivery timing, but debt dropped 55% and guidance rose on margins.

Emergent Biosolutions (NYSE:EBS) reported third-quarter revenue within its guidance range and updated its full-year outlook, while continuing a multiyear transformation focused on cost control, debt reduction, medical countermeasures and naloxone access. The company recorded third-quarter revenue o

MCM deliveries surge but naloxone competition forces restructuring and guidance cuts.

Emergent Biosolutions (NYSE:EBS) reported second-quarter 2026 revenue and adjusted EBITDA above its prior guidance and analyst consensus, driven by accelerated medical countermeasure deliveries to U.S. government customers. The company also lowered its full-year outlook as increased competition and

Emergent (EBS) Q1 2026 Earnings Transcript

Emergent (EBS) Q4 2025 Earnings Transcript

The board authorized a new $50 million share repurchase program running through March 2027.

New York State Attorney General Letitia James inked a settlement with Emergent under which the company will pay $900,000 in penalties.

Emergent BioSolutions (EBS) Earnings Transcript

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Shares of Emergent BioSolutions jumped 18% in after-hours trading after the company posted stronger-than-expected Q3 results and raised its full-year guidance.

The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.